Description:

NRF2playsacrucialroleincellularanti-oxidantdefense,makingitatherapeutictargetforneurodegenerativediseasesandcancer. Underunstressedconditions,NRF2iskeptinthecytoplasmbyaclusterofproteinsthatdegradeitquickly. Underoxidativestress,NRF2isnotdegraded,butinsteadtranslocatestothenucleuswhereitbindstoaDNApromoterandinitiatesgeneexpression. Inthenucleus,NRF2formsaheterodimerwithasmallMafproteinandbindstotheAntioxidantResponseElementintheupstreampromoterregionofmanyantioxidativegenes,andinitiatestheirtranscription.SignosishasdevelopedtheNRF2ELISAkitfortheanalysisoftheNRF2pathwayandtofacilitatestudyingactivationofdifferentNRF2-relatedpathways.

Principle:

TFELISAkitishighsensitiveandspecificassaywithasimpleandoptimizedprocedure.The96-well(8X12strip)whiteplateispre-immobilizedwiththeTFconsensussequencingoligo.TheactivatedTFinnuclearextractorthewholecelllysateisaddedinthewellandbindstotheoligo.TheactivatedTFisdetectedwithaspecificantibodyagainstthesubunitandaHRPconjugatedsecondaryantibody. Afterincubation,thewellsarewashedtoremoveunbound-labeledantibodies.TheplateisfurtherdetectedwithHRPluminescentsubstrate.Luminescenceisreportedasrelativelightunits(RLUs)onamicroplateluminometer.Thelevelofexpressionforeachspecificcytokineisdirectlyproportionaltotheluminescentintensity.

Data:

AnalysisofNRF2activationwithNRF2ELISAinTBHQ-TreatedHeLaCells.

TheHeLacellsweretreatedwith50uMTBHQovernight.ThenuclearextractswerepreparedandsubjectedtoNRF2ELISAkit.

Signosis 是一家专业的生物分析供应商，致力于基于微孔板分析技术的生命科学研究产品的开发、生产和销售。Signosis 成立于2007年，坐落于世界研发中心--美国硅谷的中心地带。公司专注于细胞因子、转录因子、miRNA及疾病标志物等重要调控因子和标志物的研究，基于自有专利技术，开发完成400多种先进而独特的用于发现、筛选和分析的生命科学研究产品。Signosis 产品销售遍布北美、欧洲、亚洲及中东等主要国家和地区，客户涵盖美国国立卫生研究院、哈佛大学、耶鲁大学等著名研究机构以及众多制药公司